On the fly News and insights, exclusive to thefly.com

2020-07-08 13:08:12 OPK Opko Health $4.03 / +0.2 (+5.22%) , PFE Pfizer $33.72 / -0.31 (-0.91%) 13:08 07/08/20 07/08 13:08 07/08/20 13:08	Opko Health price target raised to $6 from $4 at Piper Sandler Piper Sandler analyst Edward Tenthoff raised the firm's price target on Opko Health (OPK) to $6 from $4 and reiterates an Overweight rating on the shares. The stock in afternoon trading is up 5% to $4.04. The analyst says "continued strong" SARS-CoV-2 PCR and growing antibody testing at BioReference Labs increases his confidence in the company's Service revenue forecast of $225M in Q2 and $896M this year. Further, partner Pfizer (PFE) will file in the Biologics License Application and Market Authorization Application for once-weekly somatrogon for treatment of growth hormone deficiency children this year, Tenthoff tells investors in a research note. OPK Opko Health $4.03 / +0.2 (+5.22%) PFE Pfizer $33.72 / -0.31 (-0.91%)	08 Jul 10 Jul 28 Jul 25 Oct

2020-07-08 13:08:12

OPK

Opko Health

$4.03 / +0.2 (+5.22%)

, PFE

Pfizer

$33.72 / -0.31 (-0.91%)

13:08

07/08/20

07/08

13:08

07/08/20

13:08

Opko Health price target raised to $6 from $4 at Piper Sandler

Piper Sandler analyst Edward Tenthoff raised the firm's price target on Opko Health (OPK) to $6 from $4 and reiterates an Overweight rating on the shares. The stock in afternoon trading is up 5% to $4.04. The analyst says "continued strong" SARS-CoV-2 PCR and growing antibody testing at BioReference Labs increases his confidence in the company's Service revenue forecast of $225M in Q2 and $896M this year. Further, partner Pfizer (PFE) will file in the Biologics License Application and Market Authorization Application for once-weekly somatrogon for treatment of growth hormone deficiency children this year, Tenthoff tells investors in a research note.

OPK

Opko Health